Effect of pegylated interferon alpha 2b plus ribavirin treatment on plasma transforming growth factor-&beta;1, metalloproteinase-1, and tissue metalloproteinase inhibitor-1 in patients with chronic hepatitis C

doi:10.3748/wjg.v11.i43.6833

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 43

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2613)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

349

HTML

1969

Figures (1-2)

172

Tables (1-4)

123

Sum=2613

Nov 21, 2005 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Nov 21, 2005; 11(43): 6833-6838
Published online Nov 21, 2005. doi: 10.3748/wjg.v11.i43.6833

Open in New Tab Full Size Figure Download Figure

Figure 2 Mean TGF-β1 (A), TIMP-1 (B), and MMP-1 (C) plasma concentrations before and during IFN-α plus RBV therapy as well as 24 wk after its completion (wk 72) in respect to the treatment efficacy. Statistical significance in comparison to normal values is indicated with asterisks and between groups with arrows.

Open in New Tab Full Size Figure Download Figure

Figure 1 Mean score values of histologic changes in liver biopsy specimens before (wk 0) and after (wk 48) treatment. Statistically significant difference is indicated with arrows.

Citation: Flisiak R, Jaroszewicz J, Łapiński TW, Flisiak I, Prokopowiczi D. Effect of pegylated interferon alpha 2b plus ribavirin treatment on plasma transforming growth factor-β1, metalloproteinase-1, and tissue metalloproteinase inhibitor-1 in patients with chronic hepatitis C. World J Gastroenterol 2005; 11(43): 6833-6838
URL: https://www.wjgnet.com/1007-9327/full/v11/i43/6833.htm
DOI: https://dx.doi.org/10.3748/wjg.v11.i43.6833